IL131598A - Use of a reovirus for the manufacture of a medicament for the treatment of ras-mediated neoplasia - Google Patents

Use of a reovirus for the manufacture of a medicament for the treatment of ras-mediated neoplasia

Info

Publication number
IL131598A
IL131598A IL13159898A IL13159898A IL131598A IL 131598 A IL131598 A IL 131598A IL 13159898 A IL13159898 A IL 13159898A IL 13159898 A IL13159898 A IL 13159898A IL 131598 A IL131598 A IL 131598A
Authority
IL
Israel
Prior art keywords
reovirus
medicament
manufacture
ras
treatment
Prior art date
Application number
IL13159898A
Other languages
English (en)
Other versions
IL131598A0 (en
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of IL131598A0 publication Critical patent/IL131598A0/xx
Publication of IL131598A publication Critical patent/IL131598A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12261—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL13159898A 1997-08-13 1998-08-12 Use of a reovirus for the manufacture of a medicament for the treatment of ras-mediated neoplasia IL131598A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/911,383 US6110461A (en) 1997-08-13 1997-08-13 Reovirus for the treatment of neoplasia
PCT/CA1998/000774 WO1999008692A1 (en) 1997-08-13 1998-08-12 Reovirus for the treatment of neoplasia

Publications (2)

Publication Number Publication Date
IL131598A0 IL131598A0 (en) 2001-01-28
IL131598A true IL131598A (en) 2005-03-20

Family

ID=25430159

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13159898A IL131598A (en) 1997-08-13 1998-08-12 Use of a reovirus for the manufacture of a medicament for the treatment of ras-mediated neoplasia

Country Status (15)

Country Link
US (9) US6110461A (es)
EP (3) EP1213023A1 (es)
JP (1) JP4291884B2 (es)
AT (1) ATE213948T1 (es)
AU (1) AU731810B2 (es)
CA (1) CA2283280C (es)
DE (2) DE1003534T1 (es)
DK (1) DK1003534T3 (es)
ES (1) ES2157870T3 (es)
GR (1) GR20010300030T1 (es)
HK (1) HK1028340A1 (es)
IL (1) IL131598A (es)
NZ (1) NZ337493A (es)
PT (1) PT1003534E (es)
WO (1) WO1999008692A1 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6565831B1 (en) 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
AU2005201079C1 (en) * 1999-04-15 2008-11-06 Wellstat Biologics Corporation Treatment of neoplasms with viruses
MXPA01010393A (es) * 1999-04-15 2004-04-02 Pro Virus Inc Tratamiento de neoplasmas con virus.
US6586411B1 (en) 2000-08-16 2003-07-01 Mayo Foundation For Medical Education And Research System for monitoring the location of transgenes
US8147822B1 (en) * 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
US6896881B1 (en) * 1999-09-24 2005-05-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
CA2720361A1 (en) 1999-11-12 2001-05-25 Oncolytics Biotech, Inc. Viruses for the treatment of cellular proliferative disorders
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
AR028039A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US20020147996A1 (en) * 2000-07-07 2002-10-10 Benjamin Thomas L. Diagnosing and treating cancer cells using Sal2
US20050013803A1 (en) * 2000-07-07 2005-01-20 Benjamin Thomas L. Diagnosing and treating cancer cells using mutant viruses
US20020156039A1 (en) * 2000-07-07 2002-10-24 Benjamin Thomas L. Diagnosing and treating cancer cells using Sal2
US20030157481A1 (en) * 2001-12-10 2003-08-21 Benjamin Thomas L. Diagnosing and treating cancer cells using T-HR mutants and their targets
TWI289158B (en) * 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
US7118740B1 (en) * 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
EP1332366B1 (en) 2000-11-09 2010-06-30 Oncolytics Biotech, Inc. Methods for the Assessment of Cellular Proliferative Disorders
BR0115127A (pt) * 2000-11-20 2004-02-17 Oncolytics Biotech Inc Método de fornecer um vìrus a um tumor sólido para reduzir crescimento do tumor
WO2002042468A2 (en) 2000-11-27 2002-05-30 Geron Corporation Glycosyltransferase vectors for treating cancer
CA2430495A1 (en) * 2000-12-01 2002-06-06 University Of Ottawa Oncolytic virus
AR035227A1 (es) 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
EP2253701B1 (en) 2001-03-16 2014-08-13 Oncolytics Biotech Inc. Method of extracting virus from cell culture
AU2002335667A1 (en) * 2001-08-03 2003-02-17 Board Of Regents, The University Of Texas System Modified reoviral therapy
US20040115170A1 (en) * 2001-11-30 2004-06-17 Brown Earl Garnet Oncolytic virus
CA2374388C (en) * 2002-02-28 2005-07-12 Matthew C. Coffey The use of ribozymes in the detection of adventitious agents
US20040005546A1 (en) * 2002-02-28 2004-01-08 Oncolytics Biotech Inc. Use of ribozymes in the detection of adventitious agents
US7319001B2 (en) 2002-03-09 2008-01-15 Neurogenex Co., Ltd. High throughput system for producing recombinant viruses using site-specific recombination
BR0309659A (pt) 2002-04-30 2005-02-22 Oncolytics Biotech Inc Método para produzir vìrus de uma cultura de células, composição, e, método para produzir reovìrus infeccioso
CA2484398C (en) * 2002-05-09 2014-01-21 Oncolytics Biotech Inc. Method for reducing pain using oncolytic viruses
EP1944035A1 (en) 2002-05-09 2008-07-16 Oncolytics Biotech Inc. Method for reducing pain using oncolytic viruses
AU2003238008A1 (en) * 2002-06-12 2003-12-31 Temple University Of The Commonwealth System Of Higher Education Method of cell growth inhibition with agnoprotein
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
AU2002953436A0 (en) * 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
WO2004060365A1 (en) * 2002-12-30 2004-07-22 American Health Foundation Compositions and methods for treating lung cancer
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
NZ542902A (en) 2003-03-27 2007-06-29 Ottawa Health Research Inst Mutant vesicular stomatitis viruses and use thereof
WO2005002607A2 (en) * 2003-07-07 2005-01-13 Oncolytics Biotech Inc. Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac
CA2575591A1 (en) * 2003-08-08 2005-02-17 Yuji Shino A pharmaceutical composition for treatment of cancers
DK1668025T3 (da) * 2003-09-26 2014-08-25 Novartis Ag Seneca Valley-virusbaserede præparater og fremgangsmåder til behandling af sygdom
US7638318B2 (en) 2003-09-26 2009-12-29 Norvartis Ag Seneca Valley virus based compositions and methods for treating disease
US20050137152A1 (en) * 2003-12-19 2005-06-23 Danny Cheung Reovirus for the prevention of neoplasia
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
US7901921B2 (en) 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
US10260049B2 (en) * 2005-08-01 2019-04-16 Virocure, Inc. Attenuated reovirus
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
BRPI0707654A2 (pt) * 2006-02-13 2011-05-10 Oncolytics Biotech Inc mÉtodo para tratar ou melhorar um tumor sàlido em um indivÍduo
EP2839837B1 (en) * 2006-09-15 2019-05-08 Children's Hospital of Eastern Ontario Research Institute Inc. Oncolytic farmington rhabdovirus
CN103710359A (zh) 2007-03-12 2014-04-09 昂科利蒂克斯生物科技公司 具有修饰的序列的呼肠孤病毒
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
TW200909581A (en) * 2007-05-21 2009-03-01 Oncolytics Biotech Inc Mutant reoviruses and methods of making and using
EP2296678A4 (en) * 2008-05-27 2012-03-21 Oncolytics Biotech Inc MODULATION OF INTERSTITIAL PRESSURE AND ONCOLYTIC VIRUS RELIEF AND DISTRIBUTION
US8470312B2 (en) * 2008-05-27 2013-06-25 Oncolytics Biotech, Inc. Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
ES2545357T3 (es) 2010-09-02 2015-09-10 Mayo Foundation For Medical Education And Research Virus de la estomatitis vesicular
US9951117B2 (en) 2010-09-02 2018-04-24 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
AU2013204555A1 (en) * 2012-04-30 2013-11-14 Oncolytics Biotech Inc. Protecting modified viruses from neutralizing antibodies using the reovirus sigma 1 protein
WO2014204275A1 (ko) * 2013-06-21 2014-12-24 한국생명공학연구원 리오바이러스를 유효성분으로 함유하는 혈관신생 억제용 조성물
CA2930629A1 (en) 2013-11-15 2015-05-21 Oncolytics Biotech Inc. Oncolytic viruses and increased cancer treatment regimens
US20230241141A1 (en) * 2020-05-20 2023-08-03 Virocure, Inc. Pharmaceutical composition for preventing or treating cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4108983A (en) * 1976-06-01 1978-08-22 The Wistar Institute Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors
SE445466B (sv) * 1977-12-01 1986-06-23 Wellcome Found Sett att foroka rotavirus in vitro
PT70556A (en) * 1978-12-20 1980-01-01 Gist Brocades Nv Vaccines against diseases caused by reo-virus and process for the preparation of those vaccines
NL7812359A (nl) * 1978-12-20 1980-06-24 Gist Brocades Nv Vaccins tegen door reo virus veroorzaakte ziektever- schijnselen en werkwijze voor het bereiden van deze vaccins.
US4490358A (en) 1982-03-01 1984-12-25 President And Fellows Of Harvard College Screening vaccines and immunization process
US4559229A (en) * 1982-07-20 1985-12-17 Research Foundation Avian proventriculitis vaccine
WO1990009441A1 (en) * 1989-02-01 1990-08-23 The General Hospital Corporation Herpes simplex virus type i expression vector
AU5275290A (en) * 1989-04-11 1990-11-05 Board Of Regents, The University Of Texas System Antitumor preparation obtained following oncolysate treatment
CA2039921A1 (en) * 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
CA2051289C (en) * 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
CA2152941C (en) * 1993-02-16 2003-04-22 Francis Mccormick Cytopathic viruses for therapy and prophylaxis of neoplasia
US5525342A (en) * 1994-05-20 1996-06-11 Akzo Nobel, N.V. Reovirus strain 2177 and vaccine containing same
US5853716A (en) * 1995-07-28 1998-12-29 Yale University Genetically engineered chimeric viruses for the treatment of diseases associated with viral transactivators
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
WO1998008541A1 (en) 1996-08-30 1998-03-05 Genzyme Corporation Inhibition of primary and/or secondary immune response to repeat adenoviral vector administration using cd40l specific antibodies
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
HUP0003911A3 (en) 1997-10-09 2007-11-28 Pro Virus Treatment of neoplasms with viruses
AR028039A1 (es) * 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
EP1332366B1 (en) * 2000-11-09 2010-06-30 Oncolytics Biotech, Inc. Methods for the Assessment of Cellular Proliferative Disorders
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
WO2003094939A1 (en) * 2002-05-10 2003-11-20 Oncolytics Biotech Inc. Sensitization of neoplastic cells to radiation therapy with oncolytic viruses
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
JP2009504687A (ja) * 2005-08-31 2009-02-05 オンコリティクス バイオテク，インコーポレーテッド 新生物に関する免疫系による認識のインビボでの増強のための、腫瘍崩壊ウイルスおよび免疫賦活剤による処置
CN103710359A (zh) * 2007-03-12 2014-04-09 昂科利蒂克斯生物科技公司 具有修饰的序列的呼肠孤病毒

Also Published As

Publication number Publication date
DE69804106D1 (de) 2002-04-11
US20020187125A1 (en) 2002-12-12
ES2157870T1 (es) 2001-09-01
EP1213023A1 (en) 2002-06-12
DE69804106T2 (de) 2002-08-14
NZ337493A (en) 2000-12-22
ES2157870T3 (es) 2002-10-16
CA2283280A1 (en) 1999-02-25
PT1003534E (pt) 2002-08-30
AU8847198A (en) 1999-03-08
US6261555B1 (en) 2001-07-17
US20090098089A1 (en) 2009-04-16
US20040265271A1 (en) 2004-12-30
DK1003534T3 (da) 2002-05-21
EP1003534B1 (en) 2002-03-06
EP1003534A1 (en) 2000-05-31
HK1028340A1 (en) 2001-02-16
WO1999008692A1 (en) 1999-02-25
JP2002511886A (ja) 2002-04-16
IL131598A0 (en) 2001-01-28
AU731810C (en) 1999-03-08
US20050123513A1 (en) 2005-06-09
US6344195B1 (en) 2002-02-05
DE1003534T1 (de) 2001-08-23
EP1433483A1 (en) 2004-06-30
CA2283280C (en) 2005-10-18
US20010048920A1 (en) 2001-12-06
GR20010300030T1 (en) 2001-08-31
US7300650B2 (en) 2007-11-27
US7476382B2 (en) 2009-01-13
JP4291884B2 (ja) 2009-07-08
AU731810B2 (en) 2001-04-05
US6576234B2 (en) 2003-06-10
ATE213948T1 (de) 2002-03-15
US20090110665A1 (en) 2009-04-30
US6110461A (en) 2000-08-29

Similar Documents

Publication Publication Date Title
IL131598A (en) Use of a reovirus for the manufacture of a medicament for the treatment of ras-mediated neoplasia
PT646012E (pt) Cura de feridas e tratamento de perturbacoes fibroticas por tgfbeta-3
TR199701212T1 (xx) �drar� tutamama halinin tedavisi i�in alfa IL- agonistlerinin kullan�lmas�.
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
GB2320431A8 (en) N-acetyl cysteine for the treatment of chronic wounds
NZ327006A (en) Use of nisin in combination with glycerol monolaurate to treat Helicobacter pylori infections
EP0909561A3 (en) Use of reboxetine for the treatment of attention-deficit/hyperactivity disorder
ES2051650A1 (es) Procedimiento para preparar un limpiador de oxigeno activo.
AU1703101A (en) Ophthalmologic implant
AU2158688A (en) Use of bezafibrate for treating diabetes
CA2008078A1 (en) Use of Dimethylpolysiloxane for the Treatment of Disorders of the Gastrointestinal Tract
DE69510545D1 (de) Cck oder gastrin modulierende 5-heterocyclicyl-1,5-benzodiazepine
TR199801298T2 (xx) ACE-engelleyicinin dispeptik semptomlar�n tedavisinde yeni t�bbi kullan�m�.
EP0167995A3 (en) (pyrrol-1-yl)-phenyl-dihydropyridazinones, their preparation and use
NZ336804A (en) Use of pramipexole in the treatment of restless legs syndrome
MX9700298A (es) Adenovirus que comprende un gen que codifica para una no sintasa.
ZA849576B (en) 1,7-diphenyl-3-methyllaza-7-cyano-8-methylnonane for use in the treatment of diseases
EP0278467A3 (en) Use of oxoquinazoline derivatives in the treatment of hyperuricemia
AU7999687A (en) Active compounds for preventing tumor metastases
HK88396A (en) 24r-scymnol and preparation and use thereof
AU613510B2 (en) Use of zofenopril for the treatment of rheumatoid arthritis
PT661058E (pt) Utilizacao de antagonistas da bradiquinina para o tratamento de doencas virais
TW207497B (es)
DE3874978D1 (de) Ponalrestat enthaltendes hyperurikaemie-mittel.
NZ331674A (en) Use of antigenic preparations comprising Helicobacter catalase for treating or preventing Helicobacter infection

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
HC Change of name of proprietor(s)
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired